engleski

Serum adiponectin levels in dementia patients and age-matched controls

Aim: Adiponectin is cytokine produced by adipose tissue and involved in inflammation and insulin resistance. Since adiponectin has neuroprotective effect on hippocampal neurons, we hypothesised that patients suffering from dementia would have lower levels of adiponectin in comparison to healthy population. Aim of our study was to assess the possible difference in adiponectin concentration between patients with Alzheimer’s disease (AD), vascular dementia (VAD) and age-matched controls. Methods: 68 patients with diagnosis of AD (median 75, range 56-94 years) and 71 patient with diagnosis of VAD (median 78, range 58-89 years) were recruited from University Department of Neurology. Control group was divided to 49 cognitively healthy individuals (median 66, range 53-83 years) and 51 individual with diagnosis of mild cognitive impairment (MCI) (median 72, range 53-81 years). Serum concentration of adiponectin was determined using immunoturbidimetric assay Adiponectin (ADPN) (Randox Laboratories Limited, Crumlin, UK). Results: Median adiponectin concentrations for the tested groups were: AD (10.5 ; range 8.4-13.3 μg/mL), VAD (10.6 ; range 7.2-13.4 μg/mL), MCI (10.4 ; range 7.8-14.8 μg/mL) and cognitively healthy controls (8.8 ; range 5.8- 13.3 μg/mL). Kruskall-Wallis statistical test showed no statistically significant differences between the tested groups (P = 0.297). Conclusion: Serum adiponectin concentration does not differ between patients suffering from AD and VAD and healthy individuals without dementia.

adiponectin ; dementia ; hKLK6

nije evidentirano